Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > July 16, 2025
Daily News
July 16, 2025
- Industry Calls for More Tailored Govt Support on Drug Loss Product Development
July 16, 2025
- Fire Breaks Out at Towa’s Yamagata Plant, Production Halted at One Building
July 16, 2025
- JCR, Acumen Hook Up to Develop BBB-Penetrating Alzheimer’s Therapy
July 16, 2025
- Japan Logs 11th Straight Year of Decline in Drug Reps, Voluntary Buyouts Likely a Major Factor
July 16, 2025
- Otsuka Bags Autoimmune Antibody Drug from Swedish Biotech
July 16, 2025
- Global Pharma Market Surges 9% to US$1.6 Trillion in 2024, Ozempic Overtakes Humira: IQVIA
July 16, 2025
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…